On Friday, Shares of LyondellBasell Industries NV (NYSE:LYB), lost -0.35% to $101.10.
LyondellBasell Industries, declared that Doug Pike, vice president of investor relations, will address investors at the Deutsche Bank Global Industrials and Basic Materials Conference in Chicago, Illinois on June 4, 2015 at 11:20 a.m. CDT. The conference will take place at The Westin Chicago River North, 320 North Dearborn Street.
LyondellBasell Industries N.V. operates as a manufacturer of chemicals and polymers, refiner of crude oil, producer of gasoline blending components, and developer and licensor of technologies for production of polymers.
Shares of Celgene Corporation (NASDAQ:CELG), declined -0.43% to $ 114.44, during its last trading session.
Celgene Corporation, plans to present at two forthcoming investor conferences in June where Celgene administration will provide an overview of the Company. The conferences will be webcast live and a link to the webcast will be accessible in the Investor Relations section of the Company’s website at www.celgene.com.
Tuesday, June 9, 2015, Celgene will present at the Goldman Sachs 36th Annual Global Healthcare Conference in Rancho Palos Verdes, CA at 10:20 am ET
Wednesday, June 10, 2015, Celgene will present at the 2015 William Blair Growth Stock Conference in Chicago at 9:40 am ET
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally.
At the end of Friday’s trade, Shares of CTI BioPharma Corp (NASDAQ:CTIC), gained 2.11% to $ 1.94.
CTI BioPharma, declared data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill. Pacritinib is an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3. Data presented at ASCO (Abstract #LBA7006) show that contrast to best accessible therapy (exclusive of a JAK inhibitor), pacritinib therapy resulted in a significantly higher proportion of patients with spleen volume reduction and control of disease-related symptoms. Data were also selected for inclusion in the official ASCO Press Program.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.
Finally, Extra Space Storage, Inc. (NYSE:EXR), ended its last trade with 0.86% loss, and close at $ 70.03.
Extra Space Storage, declared that the Company’s board of directors has declared a quarterly dividend of $0.59 per share on the common stock of the Company for the second quarter 2015. This is a 25.5% enhance over the previous quarter. The dividend is payable on June 30, 2015 to stockholders of record at the close of business on June 15, 2015.
Extra Space Storage, Inc. operates as a real estate investment trust (REIT) in the United States. It engages in property administration and development activities that comprise acquiring, managing, developing, and selling, in addition to the rental of self-storage facilities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
